BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:225Ac-PSMA-617 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of 225Ac-PSMA-617\, from ClinicalTrials.gov 
 estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04597411-11245@assetmemo.bio
DTSTAMP:20261121T005736Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:225Ac-PSMA-617: Phase 1 readout est. (NCT04597411)
DESCRIPTION:225Ac-PSMA-617\, phase 1\, Prostate Cancer.\nStudy: Study of 22
 5Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer\nEstimated primary 
 completion: 1 January 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/225ac-psma-617#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT04597411
URL:https://assetmemo.bio/drug/225ac-psma-617#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07054346-11245@assetmemo.bio
DTSTAMP:20261121T005736Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:225Ac-PSMA-617: Phase 1 readout est. (NCT07054346)
DESCRIPTION:225Ac-PSMA-617\, phase 1\, Prostate Cancer.\nStudy: Comparison 
 of 177Lu-PSMA-617 and 225Ac-PSMA-617\nEstimated primary completion: 30 Apr
 il 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/225ac-psma-6
 17#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7054346
URL:https://assetmemo.bio/drug/225ac-psma-617#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06780670-11245@assetmemo.bio
DTSTAMP:20261121T005736Z
DTSTART;VALUE=DATE:20280627
DTEND;VALUE=DATE:20280628
SUMMARY:225Ac-PSMA-617: Phase 2/3 readout est. (NCT06780670)
DESCRIPTION:225Ac-PSMA-617\, phase 2/3\, Prostate Cancer.\nStudy: Open-labe
 l Study Comparing AAA817 Versus Standard of Care in the Treatment of Previ
 ously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or
  After [177Lu]Lu-PSMA Targeted Therapy\nEstimated primary completion: 27 J
 une 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/225ac-psma-
 617#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06780670
URL:https://assetmemo.bio/drug/225ac-psma-617#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06855277-11245@assetmemo.bio
DTSTAMP:20261121T005736Z
DTSTART;VALUE=DATE:20280929
DTEND;VALUE=DATE:20280930
SUMMARY:225Ac-PSMA-617: Phase 3 readout est. (NCT06855277)
DESCRIPTION:225Ac-PSMA-617\, phase 3\, Prostate Cancer.\nStudy: Study Compa
 ring AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-p
 ositive mCRPC\nEstimated primary completion: 29 September 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/225ac-psma-617#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06855277
URL:https://assetmemo.bio/drug/225ac-psma-617#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
